Skip to main content
. Author manuscript; available in PMC: 2018 May 12.
Published in final edited form as: Eur J Cancer. 2014 May 15;50(11):1982–1992. doi: 10.1016/j.ejca.2014.04.017

Fig. 4.

Fig. 4

Protein expression analysis of Her-2 overexpressing invasive ductal carcinoma breast cancer cell line, BT-474, upon treatment with lead compounds for hsp90 client protein degradation and hsp70 upregulation, two hallmark features of hsp90 inhibition. (A) Representative picture showing concentration dependent degradation of Hsp90 client proteins, Her-2, Akt and their phospho forms upon treatment with ONO4140. Geldanamycin (GA, 500 nM) and DMSO (1%) were used as positive and negative controls. (B) Representative picture showing concentration dependent upregulation of hsp70 (inducible) with no effect on total hsp90 levels upon treatment with ONO4140 in BT-474 cell line. Geldanamycin (GA, 500 nM) and DMSO (1%) were used as positive and negative controls.